Evidence map›Paper›PMID 35674868›Full record

ArticleCell biology and toxicology2023

Tumor-derived exosomes orchestrate the microRNA-128-3p/ELF4/CDX2 axis to facilitate the growth and metastasis of gastric cancer via delivery of LINC01091.

Qiang Wang, Chunmei Zhang, Shengya Cao, Hongying Zhao, Rongke Jiang, Yanfang Li

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biology and toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. NCellular and molecular life sciences : CMLS · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Qiang Wang *Department of Radiotherapy, Xuzhou Cancer Hospital, Xuzhou Third People's Hospital, Xuzhou, 221005, People's Republic of China.
Chunmei Zhang *Department of Medical Oncology, Jiangsu University, Zhenjiang, 212013, People's Republic of China.
Shengya Cao *Clinical Laboratory, Xuzhou Cancer Hospital, Xuzhou Third People's Hospital, Xuzhou, 221005, People's Republic of China.
Hongying ZhaoDepartment of Medical Oncology, Xuzhou Cancer Hospital, Xuzhou Third People's Hospital, No. 131, Huancheng Road, Xuzhou, 221005, People's Republic of China. xzszlyyzhao@163.com.
Rongke JiangDepartment of Hematology and Oncology, Xuzhou Cancer Hospital, Xuzhou Third People's Hospital, Xuzhou, 221005, People's Republic of China.
Yanfang LiDepartment of Medical Oncology, Xuzhou Cancer Hospital, Xuzhou Third People's Hospital, No. 131, Huancheng Road, Xuzhou, 221005, People's Republic of China.
Jiangsu University · CNXuzhou Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been manifested that tumor-derived exosomes (Exos) can deliver long noncoding RNAs to participate in gastric cancer (GC) progression. In this research, we intended to dissect out whether tumor-derived Exos carried LINC01091 to afflict the growth and metastasis of GC. GC tissues and human GC cells were attained for RNA and protein quantification. Accordingly, LINC01091, ELF4, and CDX2 were abundant but microRNA (miR)-128-3p was underexpressed in GC tissues and cells. Exos were isolated from LINC01091-silenced GC cells (Exo-sh-LINC01091). GC cells were co-cultured with Exo-sh-LINC01091 or manipulated with miR mimic, inhibitor, or overexpressing or silencing plasmids. Exo-sh-LINC01091, LINC01091, ELF4 or CDX2 silencing, or miR-128-3p upregulation augmented GC cell proliferative, migrating, and invasive properties. In addition, luciferase, RNA pull-down, and ChIP assays offered evidence supporting the mechanism that LINC01091 bound to miR-128-3p that inversely targeted ELF4, and ELF4 transcriptionally activated CDX2 by binding to its promoter in GC cells. Moreover, Exo-sh-LINC01091 modulated the miR-128-3p/ELF4/CDX2 axis and restrained the tumorigenesis and metastasis in vivo. Conclusively, LINC01091 shuttled by tumor-derived Exos might expedite GC development by activating the ELF4/CDX2 axis via miR-128-3p downregulation.

Indexed as

ExosomesMicroRNAsStomach NeoplasmsCDX2 Transcription FactorCell Line, TumorCell ProliferationDNA-Binding ProteinsGene Expression Regulation, NeoplasticHumansTranscription FactorsCDX2 protein, humanCDX2 Transcription FactorDNA-Binding ProteinsELF4 protein, humanMicroRNAsMIRN128 microRNA, humanTranscription FactorsCDX2ELF4Gastric cancerGrowthLINC01091MetastasisMicroRNA-128-3pTumor-derived exosomes

Identifiers

PMID35674868
OpenAlexW4281766357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.